Prostate cancer is positioned as the second most common cancer in men worldwide and in Spain it is the most diagnosed tumor. Prostate cancer usually does not produce symptoms, therefore, in addition to effective treatment with the best techniques, early diagnosis is essential. Currently, new procedures have been developed for the treatment of prostate cancer that seek to provide patients with a better recovery and a higher success rate compared to traditional techniques.
Atrys Oncology, a reference in radiation oncology.
Atrys is one of the leaders in the field of treatments and advances in radiation oncology. These advances, in which Dr. Benjamín Guix Melcior, specialist in oncology and director of Atrys IMOR, and Dr. Marco Panichi, specialist in radiotherapy oncology and director of Atrys IOA, are working on, aim to revolutionize the treatment of prostate cancer.
More precision and less toxicity
According to Dr. Guix, brachytherapy stands out for its high precision in treatment while reducing both side effects and risks for the patient. “Brachytherapy allows the dose to be increased inside the prostate without increasing it in neighboring healthy tissues. This technique is indicated in low-risk tumors as the only treatment or in high-risk ones as a complement to radiotherapy,” says the doctor. On the other hand, Dr. Panichi comments on the enormous advantages of it compared to traditional treatments. “Not only did we achieve a cure rate very similar to that of surgery, but we managed to reduce toxicity and shorten the treatment,” says the doctor.
Stereotactic radiation therapy (SBRT), the PACE-A study
Stereotactic radiotherapy offers the patient superior efficacy in less time. “From a more traditional treatment, of 40 sessions, we went on to an intermediate treatment for all prostate cancers, of between 20 and 28 sessions, until very fast, extremely precise treatments were achieved, such as stereotactic radiotherapy, which is performed in a total of five sessions”, says Dr. Panichi. Regarding this, last February the PACE-A study was presented at the American congress “2023 ASCO Genitourinary Cancers Symposium”, which evidenced the advantages of stereotactic radiotherapy over surgery.
The results in disease control were the same in both, but from the point of view of sexual and urinary function, there was a significant advantage of SBRT over modern techniques such as robotic surgery or laparoscopic surgery.
High success rate
Both Atrys Oncology offices (IMOR and IOA) offer their patients a control rate of around 98% in low risk cases, 95% in intermediate risk and between 80-90% in high risk cases. tall or very tall.
